All In Biotech

Drug Trial Radar · NCT06757738

A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers

A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Dose Escalation (With Optional Food Effect) Study of Orally Administered TRX-100 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of TRX-100 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Aug 13, 2024

Primary completion

Jan 16, 2025

Study completion Jan 24, 2025

Sponsor

Lead sponsor
Traws Pharma, Inc.Industry
Sponsor type
Industry
First posted
Jan 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of TRX-100 (and its major active metabolite TRX-101) in Healthy Volunteers

Conditions

  • Healthy Volunteer Study

Interventions

  • TRX-100Drug

    CEN inhibitor, dosage form - capsules, dosing regimen - QD

  • PlaceboDrug

    Placebo, dosage form - capsules, dosing regimen - QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the safety and tolerability of a single oral administration of TRX-100Time frame: up to Day 28
  2. To assess the safety and tolerability of a single oral administration of TRX-100Time frame: up to Day 28
  3. To assess the safety and tolerability of a single oral administration of TRX-100Time frame: up to Day 28
  4. To assess the safety and tolerability of a single oral administration of TRX-100Time frame: up to Day 28
  5. To assess the safety and tolerability of a single oral administration of TRX-100Time frame: up to Day 28
  6. To assess the safety and tolerability of a single oral administration of TRX-100Time frame: up to Day 28
  7. To assess the safety and tolerability of a single oral administration of TRX-100 aTime frame: up to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Sydney, Greater Sydney Area, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.